01Mar 2025
Guselkumab and Ustekinumab Show Highest Persistence in Psoriasis Treatment

Guselkumab and Ustekinumab Show Highest Persistence in Psoriasis Treatment

The study analyzed drug persistence in 709 Finnish patients (2018–2020), with guselkumab (90%) and ustekinumab (85%) showing the highest one-year continuation rates. Lower discontinuation rates were observed for guselkumab compared to other biologics. A broader cohort (Finland: 2,745, Sweden: 10,970) confirmed these findings. Understanding treatment feasibility and effectiveness is key to improving persistence in psoriasis therapy.

  • #dermatology

Like

Save

Share